Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06605586
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-01
Brief Title:
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1b2 Trial with Tasquinimod in Patients with Myelofibrosis primary Post-PV or PostET Refractory to or Intolerant for JAK2 Inhibition the TasqForce Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HOVON 172 MF
Brief Summary:
The goal of this clinical trial is to learn if therapy can be improved in patients with myelofibrosis MF who have primary resistance or who have progressed after treatment with a Janus kinase JAK inhibitor or are intolerant for this category of drugs
The main questions it aims to answer are
To evaluate the feasibility and safety of once daily dose of tasquinimod for 24 weeks 6 cycles
To determine the optimal dose
Patients will be treated once daily with tasquinimod for a maximum period of 24 weeks 6 cycles
During the study most diagnostic procedures are part of the standard of care Different from standard of care
Participation may lead to extra visits to the outpatient clinic
Additional blood will be drawn when blood is already taken per standard of care
Bone marrow sampling at entry and at the end of the trial
MRI scans or CT-scans have to be performed
Quality-of-life questionnaires have to be filled out
The main questions it aims to answer are
To evaluate the feasibility and safety of once daily dose of tasquinimod for 24 weeks 6 cycles
To determine the optimal dose
Patients will be treated once daily with tasquinimod for a maximum period of 24 weeks 6 cycles
During the study most diagnostic procedures are part of the standard of care Different from standard of care
Participation may lead to extra visits to the outpatient clinic
Additional blood will be drawn when blood is already taken per standard of care
Bone marrow sampling at entry and at the end of the trial
MRI scans or CT-scans have to be performed
Quality-of-life questionnaires have to be filled out
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None